This study was a @-week , Phase III , multicenter , randomized , blinded , double-dummy , parallel-group study of the once-daily , inhaled , fixed-dose combination of the long-acting muscarinic antagonist umeclidinium bromide and the long-acting @-agonist vilanterol ( UMEC/VI @ / @ mcg ) versus tiotropium ( TIO , @ mcg ) .